Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Harpoon Therapeutics Yönetim
Yönetim kriter kontrolleri 3/4
Harpoon Therapeutics' CEO is Julie Eastland, appointed in Nov 2021, has a tenure of 2.33 years. total yearly compensation is $1.16M, comprised of 48.7% salary and 51.3% bonuses, including company stock and options. directly owns 0.016% of the company’s shares, worth $80.60K. The average tenure of the management team and the board of directors is 1.4 years and 5.5 years respectively.
Anahtar bilgiler
Julie Eastland
İcra Kurulu Başkanı
US$1.2m
Toplam tazminat
| CEO maaş yüzdesi | 48.7% |
| CEO görev süresi | 2.3yrs |
| CEO sahipliği | 0.02% |
| Yönetim ortalama görev süresi | 1.4yrs |
| Yönetim Kurulu ortalama görev süresi | 5.5yrs |
Son yönetim güncellemeleri
Recent updates
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified
Jan 30
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough
Oct 01Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts
Aug 14Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically
May 28Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely
Mar 11Harpoon Therapeutics appoints Luke Walker as CMO
Oct 04Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player
Sep 01Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation
Jul 30Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio
Jul 07Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?
Mar 08We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate
Nov 30Harpoon Therapeutics: A First Look
Sep 16Harpoon shares slide after early-stage prostate cancer study data fails to impress
Jun 04CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$1m | US$565k | -US$68m |
| Sep 30 2022 | n/a | n/a | -US$71m |
| Jun 30 2022 | n/a | n/a | -US$76m |
| Mar 31 2022 | n/a | n/a | -US$75m |
| Dec 31 2021 | US$2m | US$84k | -US$117m |
Tazminat ve Piyasa: Julie's total compensation ($USD1.16M) is below average for companies of similar size in the US market ($USD2.19M).
Tazminat ve Kazançlar: Julie's compensation has been consistent with company performance over the past year.
CEO
Julie Eastland (59 yo)
2.3yrs
Görev süresi
US$1,160,774
Tazminat
Ms. Julie M. Eastland, M.B.A. served as Chief Operating Officer and Chief Financial Officer at Recode Therapeutics, Inc. since October 2020 until November 2021. She serves as the President and Chief Execut...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 2.3yrs | US$1.16m | 0.016% $ 80.6k | |
| Chief Medical Officer | 1.4yrs | US$668.96k | 0% $ 0 | |
| Interim Chief Financial Officer | no data | Veri yok | Veri yok | |
| Senior Vice President of Product Development | 1.3yrs | Veri yok | Veri yok | |
| Chief Legal Officer | less than a year | Veri yok | Veri yok | |
| Chief People Officer | 1.7yrs | Veri yok | Veri yok | |
| Senior Vice President of Translational Medicine | 1.7yrs | Veri yok | Veri yok | |
| Senior Vice President of Business Development | less than a year | Veri yok | Veri yok |
1.4yrs
Ortalama Görev Süresi
56.5yo
Ortalama Yaş
Deneyimli Yönetim: HARP's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 5.4yrs | US$1.16m | 0.016% $ 80.6k | |
| Independent Director | 6.8yrs | US$59.56k | 0.036% $ 179.5k | |
| Independent Director | 4yrs | US$58.56k | 0% $ 0 | |
| Independent Director | 1.5yrs | US$37.76k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 5.5yrs | US$58.56k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Chairman of the Board | 5.6yrs | US$109.62k | 0.083% $ 406.5k | |
| Independent Director | 4yrs | US$62.06k | 0% $ 0 | |
| Independent Director | 6.8yrs | US$59.56k | 0.036% $ 179.5k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok |
5.5yrs
Ortalama Görev Süresi
58.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: HARP's board of directors are considered experienced (5.5 years average tenure).